NETTLE Study: NeuroEndocrine Tumour Therapy with Lutetium-177 octreotate and Everolimus. A Phase I/II study of Everolimus in combination with Lutetium-177 octreotate for the treatment of advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Trial Profile

NETTLE Study: NeuroEndocrine Tumour Therapy with Lutetium-177 octreotate and Everolimus. A Phase I/II study of Everolimus in combination with Lutetium-177 octreotate for the treatment of advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary) ; Capecitabine; Everolimus; Temozolomide
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms NETTLE
  • Most Recent Events

    • 01 Aug 2015 Status changed from not yet recruiting to recruiting, according to results published in the Cancer Biotherapy and Radiopharmaceuticals.
    • 02 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top